DPDP Compliance for Pharma Companies: HCP, Patient Support and Clinical Trial Data

DPDP compliance for pharma requires companies to review how they collect and use personal data across doctor engagement, patient support, clinical research and drug safety operations. Each activity serves a different purpose, with its own consent, access and retention considerations.

For legal, compliance and commercial leaders, the priority is to connect these decisions with everyday workflows: how a medical representative adds a doctor to the CRM, how a vendor enrolls a patient, and how a safety team handles an adverse event report.

The core processing obligations under the Digital Personal Data Protection Act, 2023 are scheduled to commence on 13 May 2027. Pharma companies can use the preparation period to establish the processes, responsibilities and technology needed to support them.

What does DPDP compliance for pharma cover?

The DPDP framework covers digital personal data, including information collected offline and subsequently digitized. Relevant pharma records can include identifiable healthcare professionals, patients, caregivers and clinical trial participants.

A company that determines why and how personal data is processed acts as a Data Fiduciary. A provider processing information on its behalf acts as a Data Processor. These roles depend on the activity and the decisions each organization makes

Your data inventory should cover:

• HCP engagement: doctor profiles, contact details, event registrations and interaction histories.

• Patient support: enrolment forms, eligibility documents, call recordings and adherence records.

• Clinical research: participant records, trial systems and research partner access.

• Pharmacovigilance: adverse event reports, follow-up information and safety databases.

• Vendor operations: agency exports, spreadsheets, messaging tools and outsourced platforms.

Pharmaceutical data privacy in India requires these workflows to be reviewed together. Different teams may hold information about the same person while using it for different purposes.

For the provider-side perspective, read our guide to DPDPA for healthcare, patient consent and Data Principal Rights.

Do pharma companies need consent to contact doctors?

HCP consent depends on the source of the information and its proposed use. Professional contact details can qualify as personal data; an existing business relationship does not create a general exemption.

Section 7(a) can apply to a specified purpose for which an individual voluntarily provides personal data without indicating refusal. Section 3(c)(ii) separately excludes data made publicly available by the individual, or by someone legally required to publish it. Purchased directories need to be checked against those conditions.

For example, a doctor may share an email address to receive a requested scientific paper. Using that interaction to enroll the doctor in an ongoing promotional campaign requires a separate assessment.

A practical HCP consent process should record the data source, communication purpose, applicable legal ground and supporting evidence. Where consent applies, retain the notice version, date, channel and individual’s choice.

For your field-force CRM, purpose-level permissions can distinguish scientific information requests, event invitations and promotional communication. Campaign systems should receive relevant preference and withdrawal updates before the next outreach.

DPDP compliance software should be evaluated against these workflows, alongside the communication and platform requirements applicable to each channel.

How should patient support programs collect consent?

Patient support program consent should explain the personal data collected and the specific services it enables. Rule 3 requires an understandable, standalone notice describing the data and purposes, with accessible routes for withdrawal, rights and complaints.

The enrolment process should distinguish between:

• Program administration and eligibility checks.

• Medicine delivery or financial assistance coordination.

• Nurse calls, treatment education and adherence reminders.

• Optional promotional communication.

• Safety information entering a pharmacovigilance workflow.

You should map these activities before designing the consent form. A broad statement covering all future business uses provides limited clarity about the choices available.

Consider a hypothetical patient who joins a medicine assistance program and declines optional brand communication. That distinction should remain visible to the call center, delivery partner and campaign team.

Where a caregiver completes enrolment, document their role and assess the authority required for the relevant action. An adult patient’s family member should not automatically be treated as authorized to make every privacy decision.

Individuals can withdraw consent. Patient support program consent therefore needs an accessible withdrawal process and an explanation of the consequences.

Operationally, the process should identify which activities stop and route any continuing safety or recordkeeping requirements for a separate legal assessment.

Can pharmacovigilance data be processed without consent?

Some pharmacovigilance processing may qualify for a statutory ground. Section 7(d) concerns processing to meet an Indian legal obligation to disclose information to the State or its instrumentalities. Its application needs to be mapped to the specific reporting obligation and processing involved.

Medical-emergency and public-health provisions also have defined conditions. Routine safety processing requires an assessment against those conditions before relying on them.

CDSCO describes pharmacovigilance systems for collecting, processing and forwarding adverse drug reaction information to the licensing authority, and publishes guidance for marketing authorization holders.

Legal and pharmacovigilance teams should jointly document:

• The applicable reporting obligation and necessary information.

• The justification for collection, follow-up, disclosure and retention.

• Access permissions for safety personnel and vendors.

• The response when someone withdraws optional program consent.

This is a workflow-specific legal assessment. A ground supporting regulatory reporting should not automatically be extended to commercial profiling or promotional contact.

Pharmacovigilance data should have controlled access and a documented route into the safety system. Commercial teams can receive the operational information they need without routinely accessing identifiable safety case details.

How does DPDP affect clinical trial data?

Clinical trial data under DPDP needs a processing-specific assessment. Section 17(2)(b) makes the research exemption conditional on avoiding decisions specific to a Data Principal and meeting prescribed standards. Rule 16 refers to the Second Schedule.

Trial teams should assess recruitment, participant management, safety follow-up, statistical analysis and future research separately.

Clinical trial participation also has its own informed-consent and ethics requirements. CDSCO describes Ethics Committee oversight of trial proposals, recruitment and informed-consent documents under the New Drugs and Clinical Trials Rules, 2019.

Your research review should establish:

• Which organization determines each processing purpose.

• What identifiable information sponsors, sites and research partners receive.

• Whether secondary research fits the documented permissions or exemption conditions.

• Which records must remain available for regulatory purposes.

• How participant requests reach the responsible organizations.

Coding participant records is a useful safeguard. Restrict access to re-identification information and document who holds the linking records.

How should pharma companies implement DPDP compliance?

DPDP compliance for pharma requires legal decisions to translate into system behavior. The following operating practices can help teams organize implementation.

Map purposes, systems and vendors

Create a data inventory across HCP engagement, patient support, research and safety operations. Record collection sources, purposes, recipients, access permissions and retention arrangements.

Include overseas access and global providers in the review. Assess each vendor according to its actual processing role.

Review historical CRM and program records

Check the source, permitted uses and available evidence for existing doctor lists and patient databases. A CRM migration should preserve those restrictions.

Where evidence is incomplete, define the review or remediation needed before activating records for a campaign.

Establish vendor responsibilities

Recommended contract provisions include permitted purposes, access restrictions, subcontracting, incident escalation, rights assistance and data deletion or return.

You should also test the operational hand-off. A permission change needs to reach the vendor responsible for the next call or message.

Connect withdrawal and rights handling

Assign responsibility for access, correction, erasure and grievance handling. The DPDP framework provides these rights, subject to applicable conditions.

The workflow should trace requests across systems, identify applicable retention requirements and record the decision and action taken.

Test business scenarios

Useful scenarios include an HCP withdrawing promotional consent, a patient leaving a support program and a vendor identifying an adverse event during a support call.

For each scenario, confirm which systems change, which teams act and what evidence remains available.

The OneConsent DPDPA readiness guide provides a broader framework for connecting discovery, consent, governance and audit preparation.

What should pharma companies evaluate in a consent management platform?

A consent management platform should be assessed against the workflows identified during readiness planning. For pharma teams, the priority is consistent handling of permissions across commercial and patient-facing systems.

When comparing a DPDP consent management platform or a broader DPDP compliance platform, ask vendors to demonstrate:

• Purpose-level HCP and patient consent records.

• Notice versioning and evidence of individual choices.

• Withdrawal updates across connected systems.

• Access controls and reviewable activity logs.

• Workflows involving outsourced program operators.

Use a realistic scenario during evaluation. A demonstration should show how a permission change affects the next operational action.

Our guide to what a consent management platform does explains the wider evaluation context.

OneConsent describes capabilities spanning data discovery and mapping, consent lifecycle management and privacy governance. These provide a starting point for discussing the workflows identified in a pharma readiness assessment. oneconsent.ai

Effective DPDP compliance for pharma starts with defined purposes and responsibilities, followed by technology evaluation against those decisions. A DPDP compliance consultation can help establish that scope before procurement.

Book a OneConsent demo to discuss your HCP engagement and patient support workflows